CNBX Pharmaceuticals issues $45K promissory note to 3i L.P. for working capital

CNBX Pharmaceuticals Inc.

Non-convertible note principal $45,000, due July 1, 2026, with 5% simple interest.
Proceeds used for immediate working capital needs.
Holder may exchange 120% of outstanding balance for equity in a future financing at the lowest price.
Payments include a 20% premium; note may be prepaid on two days' notice.

item 1.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

CNBX Pharmaceuticals Inc. entered into Promissory Note with 3i L.P. valued at $45,000 (effective 2026-03-10).

Action: entry
Agreement: notes offering
Counterparty: 3i L.P.
Value: $45,000
Effective: 2026-03-10

Exact text from the filing

On March 10 th , 2026, the Company executed a non-convertible Promissory Note with 3i L.P., a Delaware Limited Partnership for the amount of $45,000.

View on SEC.gov

312 material agreements filed in the last 30 days. Browse all material agreements →

CNBX Pharmaceuticals Inc. filing history →

Source: SEC EDGAR

accession 0001683168-26-001883

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.